Dihydroberberine

Evidence Limitations
The safety data for dihydroberberine is currently limited. While several clinical trials have been completed studying its bioavailability and metabolic effects, detailed safety and toxicology data from human studies are not extensively available in the provided evidence. Most safety information must be inferred from preclinical studies and the known safety profile of its parent compound, berberine.

Known Side Effects
Based on the available evidence, specific side effects of dihydroberberine have not been comprehensively documented in human studies. One clinical trial (NCT05896878) investigating anti-inflammatory effects in chronic opiate patients was terminated, though the reason for termination is not specified in the available data.

Contraindications
No specific contraindications for dihydroberberine are established in the provided evidence. However, given its metabolic effects on insulin secretion and glucose regulation as noted in preclinical studies, caution may be warranted in individuals with diabetes or hypoglycemia, though this requires clinical validation.

Drug Interactions
The provided evidence does not include specific drug interaction data for dihydroberberine. However, research shows it affects glucose metabolism and insulin secretion pathways, suggesting potential interactions with diabetes medications may be possible, though this has not been clinically established.

Special Populations
No specific guidance is available in the provided evidence regarding use in pregnancy, lactation, pediatric populations, or individuals with hepatic or renal impairment. The research indicates dihydroberberine has effects on liver metabolism and gut microbiota, but safety data in compromised liver function is not available.

Toxicology
While one review mentions toxicology considerations for dihydroberberine in metabolic disorders, specific toxicological data is not detailed in the available evidence. The compound's effects on cellular processes including ferroptosis and autophagy in preclinical cancer models suggest biological activity, but human safety margins have not been established.

Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before using dihydroberberine, especially if you have existing medical conditions or take medications.